102684-91-3

Basic information

• Product Name: 2-Bromo-5-(trifluoromethyl)benzaldehyde
• Synonyms: 2-Bromo-5-(trifluoromethyl)benzaldehyde;4-Bromo-3-formylbenzotrifluoride;4-Bromo-3-formylbenzotrifluoride, 6-Bromo-alpha,alpha,alpha-trifluoro-m-tolualdehyde;2-BroMo-5-(trifluoroMethyl)benzaldehyde, 95+%
• CAS NO: 102684-91-3
• Molecular Formula: C₈H₄BrF₃O
• Molecular Weight: 253.02
• Product Categories: Aryl;Organohalides;Fluorine series
• Mol File: 102684-91-3.mol

Chemical Properties

• Boiling Point: 239.1 °C at 760 mmHg
• Flash Point: 98.4 °C
• Appearance: /
• Density: 1.677 g/cm³
• Vapor Pressure: 0.0408mmHg at 25°C
• Refractive Index: 1.511
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2-Bromo-5-(trifluoromethyl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-5-(trifluoromethyl)benzaldehyde(102684-91-3)
• EPA Substance Registry System: 2-Bromo-5-(trifluoromethyl)benzaldehyde(102684-91-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 102684-91-3(Hazardous Substances Data)

Usage

Chemical Properties

Pale yellow liquid

InChI:InChI=1/C8H4BrF3O/c9-7-2-1-6(8(10,11)12)3-5(7)4-13/h1-4H

Upstream product

• 1483-55-2 2-bromo-5-trifluoromethylbenzonitrile 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 68-12-2 N,N-dimethyl-formamide 
• 869725-53-1 (2-bromo-5-(trifluoromethyl)phenyl)methanol 

Downstream Products

• 127948-49-6 2-(8-Phenyl-octa-1,7-diynyl)-5-trifluoromethyl-benzaldehyde 
• 743468-26-0 2-pent-1-ynyl-5-trifluoromethyl-benzaldehyde 
• 869725-53-1 (2-bromo-5-(trifluoromethyl)phenyl)methanol 
• 174671-50-2 5-Trifluoromethyl-1,3-dihydro-1-hydroxy-2,1-benzoxaborole 
• 905710-73-8 2-bromo-5-trifluoromethyl-1-(methoxymethoxymethyl)benzene 
• 913296-73-8 1-(2-bromo-5-(trifluoromethyl)benzyl)piperidine 
• 1226977-80-5 2-(2-phenyl-1-ethynyl)-5-(trifluoromethyl)benzaldehyde 
• 1229446-19-8 (E)-methyl 3-(4-trifluoro-2-formylphenyl)acrylate 
• 1346004-29-2 (E)-ethyl 3-(2-(1,3-dioxan-2-yl)-4-(trifluoromethyl)phenyl)acrylate 
• 1346004-35-0 ethyl 3-(2-(1,3-dioxan-2-yl)-4-(trifluoromethyl)phenyl)propanoate 
• 1346004-40-7 ethyl 3-(2-formyl-4-(trifluoromethyl)phenyl)propanoate 
• 1346004-14-5 (S,E)-ethyl 3-(2-((1-(4-methoxyphenyl)ethylimino)methyl)-4-(trifluoromethyl)phenyl)propanoate 
• 1346004-48-5 (2aR,7bR)-1-((S)-1-(4-methoxyphenyl)ethyl)-6-(trifluoromethyl)-2a,3-dihydro-1H-indeno[1,2-b]azet-2(7bH)-one 
• 1350467-58-1 (E)-ethyl 3-(2-(1-hydroxyethyl)-4-(trifluoromethyl)phenyl)acrylate 

Relevant articles and documents

Mechanistic studies of copper(I)-catalyzed 1,3-halogen migration

An ongoing challenge in modern catalysis is to identify and understand new modes of reactivity promoted by earth-abundant and inexpensive first-row transition metals. Herein, we report a mechanistic study of an unusual copper(I)-catalyzed 1,3-migration of 2-bromostyrenes that reincorporates the bromine activating group into the final product with concomitant borylation of the aryl halide bond. A combination of experimental and computational studies indicated this reaction does not involve any oxidation state changes at copper; rather, migration occurs through a series of formal sigmatropic shifts. Insight provided from these studies will be used to expand the utility of aryl copper species in synthesis and develop new ligands for enantioselective copper-catalyzed halogenation.

Hydrogen-bonding catalysis and inhibition by simple solvents in the stereoselective kinetic epoxide-opening spirocyclization of glycal epoxides to form spiroketals

Mechanistic investigations of a MeOH-induced kinetic epoxide-opening spirocyclization of glycal epoxides have revealed dramatic, specific roles for simple solvents in hydrogen-bonding catalysis of this reaction to form spiroketal products stereoselectively with inversion of configuration at the anomeric carbon. A series of electronically tuned C1-aryl glycal epoxides was used to study the mechanism of this reaction based on differential reaction rates and inherent preferences for SN2 versus SN1 reaction manifolds. Hammett analysis of reaction kinetics with these substrates is consistent with an SN2 or SN2-like mechanism (ρ = -1.3 vs ρ = -5.1 for corresponding SN1 reactions of these substrates). Notably, the spirocyclization reaction is second-order dependent on MeOH, and the glycal ring oxygen is required for second-order MeOH catalysis. However, acetone cosolvent is a first-order inhibitor of the reaction. A transition state consistent with the experimental data is proposed in which one equivalent of MeOH activates the epoxide electrophile via a hydrogen bond while a second equivalent of MeOH chelates the side-chain nucleophile and glycal ring oxygen. A paradoxical previous observation that decreased MeOH concentration leads to increased competing intermolecular methyl glycoside formation is resolved by the finding that this side reaction is only first-order dependent on MeOH. This study highlights the unusual abilities of simple solvents to act as hydrogen-bonding catalysts and inhibitors in epoxide-opening reactions, providing both stereoselectivity and discrimination between competing reaction manifolds. This spirocyclization reaction provides efficient, stereocontrolled access to spiroketals that are key structural motifs in natural products.

DP2 Antagonist and Uses Thereof

Described herein is the DP2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a

Discovery of INCB9471, a potent, selective, and orally bioavailable CCR5 antagonist with potent anti-HIV-1 activity

To identify a CCR5 antagonist as an HIV-1 entry inhibitor, we designed a novel series of indane derivatives based on conformational considerations. Modification on the indane ring led to the discovery of compound 22a (INCB9471) that exhibited high affinit

HETEROALKYL BIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and

N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin

The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R1-R9 are as defined herein.

Piperazinylpiperidine derivatives as chemokine receptor antagonists

The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR

ESTER PRODRUGS

This invention relates to ester prodrugs for alkanoic acid compounds useful as leukotriene antagonists, and pharmaceutical compositions containing such ester prodrug compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.